SCHEMBL3015782

SCHEMBL3015782

Cc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4ccccc4)cs3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
PKM P14618 1/20 0.50
GBA1 P04062 9/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
HSD11B1 P28845 2/20 0.48
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012775 0.94 MEN1 (0.51) GAAPKMGBA1L3MBTL1HSD11B1
SCHEMBL3009926 0.91 MAPT (0.46) GAAPKMGBA1L3MBTL1HSD11B1
SCHEMBL3000163 0.90 SMN1; SMN2 (0.47) GAAPKML3MBTL1HSD11B1ALDH1A1
SCHEMBL3010733 0.89 ALDH1A1 (0.48) GAAPKMGBA1L3MBTL1HSD11B1
SCHEMBL3015956 0.89 SMN1; SMN2 (0.47) GAAPKMGBA1L3MBTL1HSD11B1
SCHEMBL2998702 0.89 SMN1; SMN2 (0.47) GAAPKML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3006852 0.89 ALDH1A1 (0.48) GAAPKMGBA1L3MBTL1HSD11B1
SCHEMBL3018625 0.89 ALDH1A1 (0.60) GAAPKMGBA1L3MBTL1ALDH1A1
SCHEMBL3008662 0.89 ALDH1A1 (0.48) GAAPKMGBA1L3MBTL1HSD11B1
SCHEMBL3011417 0.89 ALDH1A1 (0.62) PKMGBA1L3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885PKM 1047/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.